ZYLET EYE DROPS

What it is

ZYLET EYE DROPS is how the CMS NADAC file names this product. The FDA NDC Directory lists it as loteprednol etabonate and tobramycin, under the trade name “Zylet”.

FDA gives its dosage form as suspension/ drops and its route as ophthalmic.

The labeler, the company named on the label, is Bausch & Lomb Incorporated.

FDA lists it under 2 Established Pharmacologic Classes: Aminoglycoside Antibacterial and Corticosteroid.

The NADAC file of 2026-10-14 prices it under 2 NDCs (National Drug Codes).

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $64.32 – $64.51 for 1 mL, depending on the NDC ($64.31703 to $64.5118 per ML), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 5, calculated based on package size.

NADAC also lists, on the row of one brand NDC, what pharmacies pay for the generic equivalent, a different product: $39.26379 per ML filed.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

What NADAC measures · NADAC explanation codes

All 2 NDCs

• 24208-0358-05 · Bausch & Lomb Incorporated · $64.31703 per ML · eff. 2026-09-23 filed
• 24208-0358-10 · Bausch & Lomb Incorporated · $64.5118 per ML · eff. 2026-09-23 filed

Other strengths, forms and brands

1 other product in the NADAC file shares the FDA nonproprietary name loteprednol etabonate and tobramycin with ZYLET EYE DROPS.

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

The middle of its 2 NDCs’ NADAC prices is $64.31703 per ML filed.

Of the 15 other products in FDA’s Aminoglycoside Antibacterial class priced per ML, 0 have a higher middle NADAC price and 15 a lower one. The one in the middle is NEOMYCIN-POLYMYXIN-HC EAR SUSP, at $3.83312 per ML filed (eff. 2026-09-23).

Of the 106 other products in FDA’s Corticosteroid class priced per ML, 0 have a higher middle NADAC price and 106 a lower one. The one in the middle is FLUNISOLIDE 0.025% SPRAY, at $1.98777 per ML filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part D paid $63.61 for 1 mL, at an average of $63.60638 per ML in 2024 (2024-01-01 to 2024-12-31) for “Zylet” and “Tobramycin/Lotepred Etab”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 8,050 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 1 mL? Is it lower than what I would pay through my insurance?
• Which NDC (the 11-digit number on the package) is this? Pharmacies pay $64.31703 to $64.5118 per ML for this product, depending on the NDC.
• How much is in the package I am getting? This page uses 1 mL; your package may hold a different amount.
• If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.